Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Feb 27, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 3, 2026
CEOIndirect holdingOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001298709-26-000002
Filed / recorded
Mar 3, 2026, 11:30 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Krystal Biotech, Inc.
Issuer CIK
1711279
Ticker
KRYS
Reporting person
Krish S Krishnan
Relationship
Director, Officer, 10% owner
Officer title
President and CEO
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Feb 27, 2026
Transaction code
M
Shares / units
4,000
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
1,429,975
Ownership form
Indirect — By Spouse
Amendment
No
Footnotes from the filing
These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Suma M. Krishnan.
16,000 restricted stock units ("RSUs") were granted on February 28, 2025 to the Reporting Person's spouse, Suma M. Krishnan. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026.
Directly beneficially owned by Suma M. Krishnan, the spouse of the Reporting Person.